Small-cell carcinoma of the lung: the prognostic significance of stage on survival

Cooksey, Judith A.; Bitran, Jacob D.; Desser, Richard K.; Kinnealey, Ann; Mintz, Uri; Colman, M.; Cimochowski, George E.; Griem, Melvin L.; DeMeester, Tom R.; Golomb, Harvey M.

doi:10.1016/0014-2964(79)90227-5

Cited by 16 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumour registry at University of São Paulo and Hospital A C Camargo was reviewed to find all cases of small cell carcinoma of the lung seen between 1994 to 1997. All slides of neuroendocrine tumours of the lung were reviewed by two pathologists (PHN and VLC), who segregated those tumours that fulfilled predefined criteria for the diagnosis of small cell carcinoma according the IASLC system 23 and received the various adjuvant chemotherapy therapies listed in Table 1. Exclusion criteria were: (1) patients submitted to radiotherapy alone or combined with other therapeutic modality; (2) patients who were treated by surgical ressection; (3) patients who had their diagnosis based only on cytopathology; and (4) patients whose histopathological material was not available for review.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung: a preliminary report

Caporrino

Saldiva²,

Farhat³

et al. 1999

Histopathology

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…Fibreoptic biopsies, with three or more cubes of 5 μm each one, were typed according to the IASLC system, 23 which was adequate for diagnosis of small cell carcinoma sufficiently differentiated (i.e. rosettes, palisades, ribbons and organoid pattern).…”

Section: Methodsmentioning

confidence: 99%

Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung: a preliminary report

Caporrino

Saldiva²,

Farhat³

et al. 1999

Histopathology

View full text Add to dashboard Cite

show abstract

“…Chemotherapy courses were repeated every 28 days, except in the CAML-HC regimen in which a CAML cycle would begin six weeks after an HC cycle. After two cycles of chemotherapy in all regimens, radiation therapy was instituted, consisting of 3000 rads in [10][11][12][13][14][15] 200-rad fractions to the primary lung lesion, hilar lymph nodes, mediastinum, and supraclavicular fossa if supraclavicular nodes were involved. After a 7-14 day rest, chemotherapy was resumed.…”

Section: Methodsmentioning

confidence: 99%

“…The seventh biennial program on current methods of immunologic research and diagnosis will be offered by The Ernest Witebsky Center for Immunology of the State University of New York at Buffalo June [1][2][3][4][5][6][7][8][9][10][11][12][13]1981. This will consist primarily of a combination of core and elective practical laboratory exercises to allow the participant to become acquainted with the techniques by personally carrying them out at the bench complemented by demonstrations, lectures, and discussions.…”

Section: Seventh Summer Program In Methods Of Immunologic Research Anmentioning

confidence: 99%

See 1 more Smart Citation

Small-cell carcinoma of the lung: A five-year experience with combined modality therapy

Hoffman

Golomb

Bitran

et al. 1980

Cancer

Self Cite

View full text Add to dashboard Cite

In the past five years, we have treated 89 patients with small-cell carcinoma of the lung with radio-therapy plus one of three chemotherapy programs. The 24 patients with disease confined to the chest (Stage IIIMo) had an 87% response rate to the combined modalities (79% complete responses) and a median survival of 18 months; 13 patients with disease confined to the chest and ipsilateral supraclavic-ular nodes (Stage IIIMoSCN+) had an 84% response rate (69% complete reponses) and 11-month median survival; the 52 patients with distant metastases (Stage IIIMI) had a 71% response rate (15% complete responses) and eight-month median survival. Survival was not affected by adding pro-phylactic cranial irradiation to the latest regimen, although the CNS relapse rate was reduced. We conclude that our three chemotherapy programs to date differ very little in their effect on survival of patients with metastatic disease. New and more vigorous approaches, possibly including surgery, need to be tested for the management of disease confined to the chest. The designation of patients as Stage III,,SCN+ is valid because such patients have better survival rates than patients with distant metastatic disease. Cancer 46:2550-2556. 1980. MALL-CELL CARCINOMA of lung is a disease S with very poor survival rates and for which the local modalities of surgery and radiotherapy have little impact on mortality.25 In the past decade, major advances have been made in the management of this tumor, principally due to the addition of combination chemotherapy programs to local modalities of treatment. These advances have been summarized in several recent reviews.7~16~23~27 Beginning in 1974, patients at the University of Chicago and Michael Reese Medical Center with small-cell bronchogenic carcinoma have been treated aggressively with a series of three successive programs combining radiation therapy and chemotherapy. Our results with 51 patients with two of the programs have been reported previously.5,10 In this paper we report the results of treatment of 38 additional patients with a third program, compare the three programs, and sum

show abstract

Sequential scintigraphic staging of small cell carcinoma

Bitran

Bekerman

Pinsky

1981

Cancer

View full text Add to dashboard Cite

Thirty patients with small cell carcinoma (SCC) of the lung were sequentially staged following a history and physical exam with liver, bran, bone, and gallium-67 citrate scans. Scintigraphic evaluation disclosed 7 of 30 patients (23%) with advanced disease, stage IIIM1. When Gallium-67 scans were used as the sole criteria for staging, they proved to be accurate and identified six of the seven patients with occult metastatic disease. Gallium-67 scans proved to be accurate in detecting thoracic and extrathoracic metastases in the 30 patients with SCC, especially within the liver and lymph node-bearing area. The diagnostic accuracy of gallium-67 fell in regions such as bone or brain. Despite the limitations of gallium-67 scanning, the authors conclude that these scans are useful in staging patients with SCC and should be the initial scans used in staging such patients.

show abstract

Small-cell carcinoma of the lung: the prognostic significance of stage on survival

Cited by 16 publications

References 8 publications

Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung: a preliminary report

Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung: a preliminary report

Small-cell carcinoma of the lung: A five-year experience with combined modality therapy

Sequential scintigraphic staging of small cell carcinoma

Contact Info

Product

Resources

About